Lumicell Submits NDA for LUMISIGHT Optical Imaging Agent for Breast Cancer Surgery

Lumicell, Inc. today announced FDA submission of the LUMISIGHTâ„¢ Optical Imaging Agent New Drug Application. LUMISIGHT is intended for use with their Lumicellâ„¢ Direct Visualization System (DVS), an investigational system designed to assist in the detection of residual cancerous tissue following removal of the primary specimen during the initial lumpectomy.

Data has shown that at least 20% of women undergoing breast conserving surgery require a second surgery due to incomplete tumor removal, and 6-10% end up experiencing a local recurrence of breast cancer. Technology like the Lumicell DVS can aid in detecting and removing residual cancer during the initial surgery, which has the potential to support improved outcomes.

The LUMISIGHT NDA submission is supported by data from 700+ breast cancer patients across five clinical studies, and results from its INSITE pivotal trial will be presented at the upcoming American Society of Breast Surgeons (ASBrS) annual meeting. LUMISIGHT was previously granted Fast Track designation by the FDA. Following its LUMISIGHT NDA submission, the company plans to submit the PMA for the Lumicell DVS in the second quarter of this year.

The Lumicell DVS is a combination product which includes the LUMISIGHT Optical Imaging Agent, a hand-held imaging probe designed to go inside the breast cavity and a patient-calibrated cancer detection software to assist in the detection of residual cancer and enable a more complete resection.

By way of introduction, Lumicell is a Massachusetts-based private company reimagining the practice of cancer surgery by utilizing innovative fluorescence-guided surgical technologies to enable a more complete resection of cancer that may have otherwise been left behind. The first indication the company is pursuing is for breast cancer.

The Lumicell DVS is designed by engineers and scientists from MIT, in close partnership with leading breast cancer surgeons, to fit seamlessly within the existing surgical workflow.

SourceLumicell
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.
The rehabilitation robotic glove is a training device that combines EMG electromyographic feedback and flexible robotics for patients with stroke or hand disabilities to train and repair dexterity.

By using this website you agree to accept Medical Device News Magazine Privacy Policy